SciClone Pharmaceuticals

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, SciClone Pharmaceuticals sits in the upper quartile of US sponsors by registered trial count (#1,806 of 15,742 sponsors by registered trial count).

7 total trials none currently recruiting 6 completed early-phase tilt upper quartile by trial count

SciClone Pharmaceuticals: 7 sponsored US clinical trials, none currently recruiting.

SciClone Pharmaceuticals sponsors 7 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 6 completed. 2 of these trials are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Chronic Hepatitis C, with 1 trials.

Upper-quartile sponsor footprint

SciClone Pharmaceuticals sits in the upper quartile of the sponsor corpus (#1,806 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Indexed trials (enrollment closed)

7 total, page 1 of 1

COMPLETED

Extension Study SCI-SCV-HCV-P2-001: Long-Term FU in Subj Who Opt for Retreatment With Peg-INF and RBV After Completing Treatment in HCV

NCT01310205
COMPLETED Phase 2

Proof-of-concept Study to Evaluate the Safety and Immunomodulatory Effects of SCV 07 as Monotherapy or in Combination With Ribavirin in Noncirrhotic Subjects With Chronic Hepatitis C Who Have Relapsed

NCT00968357
COMPLETED Phase 2

Dose Ranging Study to Assess the Safety and Efficacy of SCV-07 for the Delay to Onset of Severe Oral Mucositis in Patients Receiving Chemoradiation Therapy for Head and Neck Cancer

NCT00756951
TERMINATED Phase 2

Phase II Study to Evaluate Efficacy and Safety of RP101 in Combination With Gemcitabine

NCT00550004
COMPLETED Phase 3

Thymosin Plus PEG-Interferon in Hepatitis C Patients With Cirrhosis Who Did Not Respond to Interferon or Interferon Plus Ribavirin

NCT00039962
COMPLETED Phase 3

Thymosin Plus PEG-Interferon in Non-Cirrhotic Hepatitis C Patients Who Did Not Respond to Interferon or Interferon Plus Ribavirin

NCT00040027
COMPLETED Phase 2

A Trial of Thymalfasin in Adult Patients With Hepatocellular Carcinoma

NCT00082082

Phase Distribution

PhaseTrial count
Phase 2 4
Phase 3 2

Therapeutic Areas

Chronic Hepatitis C 1

How the SciClone Pharmaceuticals early-phase archive is shaped

7 indexed studies, none listed as recruiting (0% open); 6 completed (86%).

Phase mix: 2 late (III/IV) vs 4 early (I/II) (early-phase heavy).

Top condition: Chronic Hepatitis C (1 trial), 0 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

SciClone Pharmaceuticals: archived-pipeline peers nationwide

Peers matched on 7 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

SciClone Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%10%20%30%40% Total trials Recruiting share SciClone Pharmaceuticals3M4Life Research89bioAbbott Diagnostics Division10xBio22nd Century Group23andMe3-C Institute for Social Development
SciClone Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

SciClone Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 7 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this SciClone Pharmaceuticals page

7 registered trials is a research-attention snapshot, not an endorsement of SciClone Pharmaceuticals or any single study.

  • None of SciClone Pharmaceuticals's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Chronic Hepatitis C is the condition SciClone Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Chronic Hepatitis C trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

SciClone Pharmaceuticals pipeline card: 7 registered trials from official public datasets.Report a data error.